Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 66 entries
The Cimzia Pregnancy Exposure Registry is following pregnant women who have been treated with Cimzia during pregnancy and comparing them to pregnant women who were not exposed to Cimzia. Both groups of women and their babies will be followed up to 1 year after delivery. The goal is to determine the possible effect of Cimzia and the diseases it treats on pregnancy and infant outcomes.
We will examine adolescents with newly diagnosed Crohn’s disease at baseline and one year later to evaluate the impact of Crohn’s disease inflammatory activity on bone marrow fat, bone mineral density, bone turnover markers, and to correlate with peripheral blood molecular and immune cell parameters.
To evaluate the usefulness, safety, and effectiveness of intravenous ExoFlo in patients with Crohn’s disease who are not responding to conventional therapies.
To evaluate the usefulness, safety, and effectiveness of intravenous ExoFlo in patients with ulcerative colitis who are not responding to conventional therapies.
The purpose of the FUZION Study is to evaluate the efficacy and safety of the investigational study medication in participants with Fistulizing, Perianal Crohn’s Disease
Primary objective is to evaluate the efficacy of JNJ-77242113 versus placebo in inducing clinical response.
The purpose of the DUET study is to evaluate the efficacy and safety of the investigational combination therapy with two investigational study medications in participants with moderately to severely active Ulcerative Colitis.
The purpose of the DUET study is to evaluate the efficacy and safety of the investigational combination therapy of two investigational medications in participants with moderately to severely active Crohn's disease.
The goal of this study is to see if VE202 can help reduce inflammation in the large intestine and restore overall gut health in patients with mild to moderate ulcerative colitis. To study this, VE202 will be compared with a placebo.
Patients who completed the induction treatment of 8 weeks can roll over into a subsequent maintenance study with the objective to evaluate long-term safety and efficacy of obefazimod (ABX464). The maintenance trial consists of a 44-weeks treatment period followed by a 4-weeks follow-up period.
The Featured Study Opportunities page is made possible in part by:
